Catalyst Pharmaceuticals Inc

CN2-FF:Frankfurt Stock Exchange
RT Quote | Exchange | EUR
Last | 01/22/21 CET
2.92quote price arrow down-0.08 (-2.50%)
Volume
2,666
52 week range
2.68 - 3.00

...

Loading . . .

KEY STATS

  • Open2.96
  • Day High2.96
  • Day Low2.92
  • Prev Close2.92
  • 52 Week High3.00
  • 52 Week High Date01/20/21
  • 52 Week Low2.68
  • 52 Week Low Date01/04/21
  • Market Cap361.73M
  • Shares Out103.65M
  • 10 Day Average Volume858.83
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-22.29

RATIOS/PROFITABILITY

  • EPS (TTM)0.57
  • P/E (TTM)5.13
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Catalyst Pharmaceuticals Inc News

There is no recent news for this security.

Latest CN2-FF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of...
Patrick McEnany
Chairman
Steven Miller Ph.D.
Chief Operating Officer
Alicia Grande CPA
Chief Financial Officer
Address
355 Alhambra Cir Ste 1250
Coral Gables, FL
33134-5038
United States